- Home
- VSTM vs ETON Comparison
VSTM vs ETON Comparison
Compare VSTM & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- ETON
- Stock Information
- Founded
- VSTM 2010
- ETON 2017
- Country
- VSTM United States
- ETON United States
- Employees
- VSTM N/A
- ETON N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- ETON Health Care
- Exchange
- VSTM Nasdaq
- ETON Nasdaq
- Market Cap
- VSTM 132.0M
- ETON 199.5M
- IPO Year
- VSTM 2012
- ETON 2018
- Fundamental
- Price
- VSTM $3.88
- ETON $8.77
- Analyst Decision
- VSTM Strong Buy
- ETON Strong Buy
- Analyst Count
- VSTM 8
- ETON 3
- Target Price
- VSTM $14.57
- ETON $12.00
- AVG Volume (30 Days)
- VSTM 1.1M
- ETON 214.1K
- Earning Date
- VSTM 11-06-2024
- ETON 11-11-2024
- Dividend Yield
- VSTM N/A
- ETON N/A
- EPS Growth
- VSTM N/A
- ETON N/A
- EPS
- VSTM N/A
- ETON N/A
- Revenue
- VSTM $10,000,000.00
- ETON $31,381,000.00
- Revenue This Year
- VSTM N/A
- ETON $19.61
- Revenue Next Year
- VSTM $125.69
- ETON $35.39
- P/E Ratio
- VSTM N/A
- ETON N/A
- Revenue Growth
- VSTM N/A
- ETON 8.14
- 52 Week Low
- VSTM $2.10
- ETON $3.03
- 52 Week High
- VSTM $14.22
- ETON $8.66
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- ETON 76.07
- Support Level
- VSTM $3.11
- ETON $7.58
- Resistance Level
- VSTM $3.76
- ETON $8.66
- Average True Range (ATR)
- VSTM 0.33
- ETON 0.42
- MACD
- VSTM 0.04
- ETON -0.07
- Stochastic Oscillator
- VSTM 94.26
- ETON 91.49
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.